Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, promotes weight loss in patients with type 2 diabetes mellitus and obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.